 | This article relies largely or entirely on a single source .(November 2019) |
The American Society for Bone and Mineral Research (ASBMR) is a professional, scientific and medical society established in 1977 to promote excellence in bone and mineral research and to facilitate the translation of that research into clinical practice. The ASBMR has a membership of nearly 4,000 physicians, basic research scientists, and clinical investigators from around the world.
The mission of the ASBMR is to promote excellence in bone and mineral research, foster integration of clinical and basic science, and facilitate the translation of that science to health care and clinical practice. The Society's broad goals include supporting the educational development of future generations of basic and clinical scientists, and disseminating new knowledge in bone and mineral metabolism.
In the 1970s, a growing number of US-based scientists began to focus their research on the understanding of basic bone biology and the disease osteoporosis. This led to the rise of a new field – bone and mineral research. In 1974, while attending the annual meeting of The Endocrine Society in Chicago, Illinois, USA, bone scientists Louis Avioli, Claude Arnaud, Norman Bell, William Peck, John Potts and Lawrence Raisz, along with Shirley Hohl, met at the Drake Hotel. The group laid the groundwork for an organization that would promote the study of bone and mineral research, support scientists involved in such research, and facilitate the discussion and exchange of new developments in the field. Three years later, in November 1977, the group's goals were realized with the official incorporation of the ASBMR as a nonprofit organization in St. Louis, Missouri, USA. The first ASBMR Annual Meeting was held June 11–12, 1979, at the Disneyland Hotel in Anaheim, California, USA, with approximately 150 people in attendance.
In 1984, ASBMR leaders established The Osteoporosis Foundation, which was later renamed the National Osteoporosis Foundation.
The Journal of Bone and Mineral Research (JBMR), the official journal of the ASBMR, was established in 1986. Initially a bi-monthly publication, it became a monthly journal in 1990. Lawrence G. Raisz served as the first Editor-in-Chief of the JBMR.
The ASBMR published the first edition of The Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, a textbook for medical and graduate students, in 1990. Murray J. Favus served as the Editor-in-Chief for the first six editions of the Primer.
The rise of new pharmacological treatments for osteoporosis in the 1990s, most notably the class of drugs known as bisphosphonates, gave rise to an influx of scientists and clinician-researchers into the field. This influx resulted in a dramatic increase in ASBMR membership and annual meeting attendance. During this period, the ASBMR expanded its advocacy endeavors targeted at U.S. government funding for bone research. The Society was a founding member of the National Coalition for Osteoporosis and Related Bone Diseases ("Bone Coalition") in 1991. ASBMR also became a member of the Federation of American Societies for Experimental Biology (FASEB).
Though conceived as a scientific research society, in recent years, ASBMR has made increasing public and healthcare professional awareness of bone diseases a top priority. The Society launched several educational initiatives aimed at primary care physicians to improve the detection and treatment of bone diseases, and founded the National Bone Health Alliance to serve as a resource and raise public awareness of bone diseases. It has also spearheaded task forces on numerous clinically relevant topics, including: osteonecrosis of the jaw and atypical femoral fractures. The Society has also sought to expand the study of bone to those in related fields and to those in emerging areas of the world.
ASBMR's annual meeting brings together leading basic, translational and clinical researchers in bone from around the world. The event is held in September or October and attracts nearly 4,000 attendees each year. The scientific program includes poster presentations, plenary lectures, workshops, networking events, ancillary meetings, and a host of other activities. Hallmarks of the ASBMR Annual Meeting include the Gerald D. Aurbach Lecture, the Louis V. Avioli Lecture, and the ASBMR/ECTS Clinical Debate. Abstracts from the meeting's poster presentations are published as supplements in the JBMR.
The ASBMR began holding topical meetings in 2002 to address specialized research topics within the bone field. Smaller in scale, topical meetings disseminate and discuss in-depth research on a specific area of scientific interest.
The Journal of Bone and Mineral Research , the official journal of the ASBMR. The JBMR publishes original manuscripts, reviews, and special articles in basic and clinical science relevant to bone, muscle and mineral metabolism. Manuscripts are published on the biology and physiology of bone and muscle, relevant systems biology topics (e.g. osteoimmunology), and the pathophysiology and treatment of osteoporosis, sarcopenia and other disorders of bone and mineral metabolism. 2016 Journal Citation Reports Impact Factor was 6.3, ranking 15/138 (Endocrinology & Metabolism).
JBMR readers include basic scientists and physicians specializing in endocrinology, physiology, cell biology, pathology, molecular genetics, epidemiology, internal medicine, rheumatology, orthopaedics, geriatrics, dentistry, gynecology, molecular biology, nephrology and many other disciplines. The JBMR's international editorial board encourages manuscript submissions from around the world.
The Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism is a resource for scientists and students seeking an overview of the bone and mineral field and for clinicians who see patients with disorders of bone and mineral metabolism. The text provides valuable information on the symptoms, pathophysiology, diagnosis, and treatment of metabolic bone diseases and both common and rare disorders. Authors include internationally renowned experts in the field.
The ASBMR e-News Weekly is a member newsletter featuring society initiatives and related information on upcoming events, conferences, membership benefits, and other important information. The newsletter keeps members abreast of ASBMR activities—from Council, Committee, task force, and program updates to the role of ASBMR within the bone and mineral field and the scientific and medical community at large. Each issue also includes the most recently published articles in JBMR and highlights current noteworthy news articles pertaining to the bone field from thousands of news sources worldwide.
The Society has established numerous grant and award programs since its inception aimed at supporting the career development of its members, as well as recognizing their scientific accomplishments and contributions to the field. [1]
Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to bone sterility, and consequent increase in fracture risk. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the vertebrae in the spine, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. After the broken bone heals, the person may have chronic pain and a decreased ability to carry out normal activities.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
Bisphosphonates are a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases. They are the most commonly prescribed drugs used to treat osteoporosis. They are called bisphosphonates because they have two phosphonate groups. They are thus also called diphosphonates.
Paget's disease of bone is a condition involving cellular remodeling and deformity of one or more bones. The affected bones show signs of dysregulated bone remodeling at the microscopic level, specifically excessive bone breakdown and subsequent disorganized new bone formation. These structural changes cause the bone to weaken, which may result in deformity, pain, fracture or arthritis of associated joints.
Osteopenia, known as "low bone mass" or "low bone density", is a condition in which bone mineral density is low. Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop osteoporosis. In 2010, 43 million older adults in the US had osteopenia. Unlike osteoporosis, osteopenia does not usually cause symptoms, and losing bone density in itself does not cause pain.
Renal osteodystrophy/adynamic bone disease is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD). The term "renal osteodystrophy" was coined in 1943, 60 years after an association was identified between bone disease and kidney failure.
Hypophosphatasia (; also called deficiency of alkaline phosphatase, phosphoethanolaminuria, or Rathbun's syndrome; sometimes abbreviated HPP) is a rare, and sometimes fatal, inherited metabolic bone disease. Clinical symptoms are heterogeneous, ranging from the rapidly fatal, perinatal variant, with profound skeletal hypomineralization, respiratory compromise or vitamin B6 dependent seizures to a milder, progressive osteomalacia later in life. Tissue non-specific alkaline phosphatase (TNSALP) deficiency in osteoblasts and chondrocytes impairs bone mineralization, leading to rickets or osteomalacia. The pathognomonic finding is subnormal serum activity of the TNSALP enzyme, which is caused by one of 388 genetic mutations identified to date, in the gene encoding TNSALP. Genetic inheritance is autosomal recessive for the perinatal and infantile forms but either autosomal recessive or autosomal dominant in the milder forms.
Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the tissue in bones and release the minerals, resulting in a transfer of calcium from bone tissue to the blood.
Medical genetics is the branch of medicine that involves the diagnosis and management of hereditary disorders. Medical genetics differs from human genetics in that human genetics is a field of scientific research that may or may not apply to medicine, while medical genetics refers to the application of genetics to medical care. For example, research on the causes and inheritance of genetic disorders would be considered within both human genetics and medical genetics, while the diagnosis, management, and counselling people with genetic disorders would be considered part of medical genetics.
Sclerostin is a protein that in humans is encoded by the SOST gene. It is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced primarily by the osteocyte but is also expressed in other tissues, and has anti-anabolic effects on bone formation.
The Kolling Institute is located in the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. Primary, or involuntary osteoporosis, can further be classified into Type I or Type II. Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. While senile osteoporosis is categorized as an involuntary, Type II, and primary osteoporosis, which affects both men and women over the age of 70 years. It is accompanied by vitamin D deficiency, body's failure to absorb calcium, and increased parathyroid hormone.
Harold M. Frost was an American orthopedist and surgeon considered to be one of the most important researchers and theorists in the field of bone biology and bone medicine of his time. He published nearly 500 peer-reviewed scientific and clinical articles and 16 books. According to the Science Citation Index, he is one of the most cited investigators in skeletal research.
Richard Eastell MD, FRCP, FRCPath, FMedSci is a British medical doctor and Professor of Bone Metabolism at the University of Sheffield. He was born in Shipley and attended the Salt Grammar School, later graduating from the University of Edinburgh in 1977 with an MB ChB and in 1984 with an MD and achieved prominence as an expert in osteoporosis.
Michael F. Holick is an American adult endocrinologist, specializing in vitamin D, such as the identification of both calcidiol, the major circulating form of vitamin D, and calcitriol, the active form of vitamin D. His work has been the basis for diagnostic tests and therapies for vitamin D-related diseases. He is a professor of medicine at the Boston University Medical Center and editor-in-chief of the journal Clinical Laboratory.
The Australian and New Zealand Bone and Mineral Society (ANZBMS) is a not-for-profit collegiate organisation and principal professional body for scientists and clinicians involved in bone and mineral metabolism research in Australia and New Zealand.
Bone marrow adipose tissue (BMAT), sometimes referred to as marrow adipose tissue (MAT), is a type of fat deposit in bone marrow. It increases in states of low bone density -osteoporosis, anorexia nervosa/ caloric restriction, skeletal unweighting such as that which occurs in space travel, and anti-diabetes therapies. BMAT decreases in anaemia, leukaemia, and hypertensive heart failure; in response to hormones such as oestrogen, leptin, and growth hormone; with exercise-induced weight loss or bariatric surgery; in response to chronic cold exposure; and in response to pharmacological agents such as bisphosphonates, teriparatide, and metformin.
David Goltzman is an endocrinologist, Professor of Medicine and Physiology, and A.G. Massabki Chair in Medicine at McGill University in Montreal, Quebec, Canada. He is the Director of the Centre for Bone and Periodontal Research and also holds the position of Senior Scientist at the McGill University Health Centre Research Institute in the Metabolic Disorders and Complications Program.
Endocrine & Metabolism Research Institute (EMRI) is one of Tehran University of Medical Sciences research institute and a pioneering institute with a mission to combine clinical care, research, and education in diabetes, endocrine and metabolic diseases.
Lynda Bonewald is a professor of anatomy, cell biology, physiology, and orthopaedic surgery and the founding director of the Indiana Center for Musculoskeletal Health (ICMH) at the Indiana University School of Medicine. She studies bone and the musculoskeletal system. She has served as president of the American Society for Bone and Mineral Research and the Association of Biomolecular Resource Facilities (1999-2000).
| International | |
|---|---|
| National | |
